Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Targeting chemoresistant colorectal cancer via systemic administration of a BMP7 variant.

Veschi V, Mangiapane LR, Nicotra A, Di Franco S, Scavo E, Apuzzo T, Sardina DS, Fiori M, Benfante A, Colorito ML, Cocorullo G, Giuliante F, Cipolla C, Pistone G, Bongiorno MR, Rizzo A, Tate CM, Wu X, Rowlinson S, Stancato LF, Todaro M, De Maria R, Stassi G.

Oncogene. 2019 Oct 7. doi: 10.1038/s41388-019-1047-4. [Epub ahead of print]

PMID:
31591478
2.

Correction: By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy.

Petrelli A, Carollo R, Cargnelutti M, Iovino F, Callari M, Cimino D, Todaro M, Mangiapane LR, Giammona A, Cordova A, Montemurro F, Taverna D, Daidone MG, Stassi G, Giordano S.

Oncotarget. 2019 Aug 13;10(48):5003-5004. doi: 10.18632/oncotarget.27151. eCollection 2019 Aug 13.

3.

Correction to: Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4.

Todaro M, Lombardo Y, Francipane MG, Alea MP, Cammareri P, Iovino F, Di Stefano AB, Di Bernardo C, Agrusa A, Condorelli G, Walczak H, Stassi G.

Cell Death Differ. 2019 Dec;26(12):2808-2809. doi: 10.1038/s41418-019-0401-y.

PMID:
31395960
4.

Focused Ultrasound Effects on Osteosarcoma Cell Lines.

Agnese V, Costa V, Scoarughi GL, Corso C, Carina V, De Luca A, Bellavia D, Raimondi L, Pagani S, Midiri M, Stassi G, Alessandro R, Fini M, Barbato G, Giavaresi G.

Biomed Res Int. 2019 May 19;2019:6082304. doi: 10.1155/2019/6082304. eCollection 2019.

5.

DNA methylation of shelf, shore and open sea CpG positions distinguish high microsatellite instability from low or stable microsatellite status colon cancer stem cells.

Visone R, Bacalini MG, Di Franco S, Ferracin M, Colorito ML, Pagotto S, Laprovitera N, Licastro D, Di Marco M, Scavo E, Bassi C, Saccenti E, Nicotra A, Grzes M, Garagnani P, De Laurenzi V, Valeri N, Mariani-Costantini R, Negrini M, Stassi G, Veronese A.

Epigenomics. 2019 May 1;11(6):587-604. doi: 10.2217/epi-2018-0153. Epub 2019 May 8.

6.

Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance.

Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R.

Mol Cancer. 2019 Mar 30;18(1):70. doi: 10.1186/s12943-019-0994-2. Review.

7.

Meeting the Challenge of Targeting Cancer Stem Cells.

Turdo A, Veschi V, Gaggianesi M, Chinnici A, Bianca P, Todaro M, Stassi G.

Front Cell Dev Biol. 2019 Feb 18;7:16. doi: 10.3389/fcell.2019.00016. eCollection 2019. Review.

8.

Microenvironment in neuroblastoma: isolation and characterization of tumor-derived mesenchymal stromal cells.

Pelizzo G, Veschi V, Mantelli M, Croce S, Di Benedetto V, D'Angelo P, Maltese A, Catenacci L, Apuzzo T, Scavo E, Moretta A, Todaro M, Stassi G, Avanzini MA, Calcaterra V.

BMC Cancer. 2018 Nov 27;18(1):1176. doi: 10.1186/s12885-018-5082-2.

9.

Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer.

Lenos KJ, Miedema DM, Lodestijn SC, Nijman LE, van den Bosch T, Romero Ros X, Lourenço FC, Lecca MC, van der Heijden M, van Neerven SM, van Oort A, Leveille N, Adam RS, de Sousa E Melo F, Otten J, Veerman P, Hypolite G, Koens L, Lyons SK, Stassi G, Winton DJ, Medema JP, Morrissey E, Bijlsma MF, Vermeulen L.

Nat Cell Biol. 2018 Oct;20(10):1193-1202. doi: 10.1038/s41556-018-0179-z. Epub 2018 Sep 3.

10.

Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models.

Prasetyanti PR, van Hooff SR, van Herwaarden T, de Vries N, Kalloe K, Rodermond H, van Leersum R, de Jong JH, Franitza M, Nürnberg P, Todaro M, Stassi G, Medema JP.

Int J Cancer. 2019 Jan 15;144(2):366-371. doi: 10.1002/ijc.31767. Epub 2018 Oct 22.

11.

Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models.

Linnekamp JF, Hooff SRV, Prasetyanti PR, Kandimalla R, Buikhuisen JY, Fessler E, Ramesh P, Lee KAST, Bochove GGW, de Jong JH, Cameron K, Leersum RV, Rodermond HM, Franitza M, Nürnberg P, Mangiapane LR, Wang X, Clevers H, Vermeulen L, Stassi G, Medema JP.

Cell Death Differ. 2018 Mar;25(3):616-633. doi: 10.1038/s41418-017-0011-5. Epub 2018 Jan 5.

12.

Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer.

Meraviglia S, Lo Presti E, Tosolini M, La Mendola C, Orlando V, Todaro M, Catalano V, Stassi G, Cicero G, Vieni S, Fourniè JJ, Dieli F.

Oncoimmunology. 2017 Jul 13;6(10):e1347742. doi: 10.1080/2162402X.2017.1347742. eCollection 2017.

13.

Combined platelet-rich plasma and lipofilling treatment provides great improvement in facial skin-induced lesion regeneration for scleroderma patients.

Virzì F, Bianca P, Giammona A, Apuzzo T, Di Franco S, Mangiapane LR, Colorito ML, Catalano D, Scavo E, Nicotra A, Benfante A, Pistone G, Caputo V, Dieli F, Pirrello R, Stassi G.

Stem Cell Res Ther. 2017 Oct 23;8(1):236. doi: 10.1186/s13287-017-0690-3.

14.

Role of Type I and II Interferons in Colorectal Cancer and Melanoma.

Di Franco S, Turdo A, Todaro M, Stassi G.

Front Immunol. 2017 Jul 26;8:878. doi: 10.3389/fimmu.2017.00878. eCollection 2017. Review.

15.

IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition.

Gaggianesi M, Turdo A, Chinnici A, Lipari E, Apuzzo T, Benfante A, Sperduti I, Di Franco S, Meraviglia S, Lo Presti E, Dieli F, Caputo V, Militello G, Vieni S, Stassi G, Todaro M.

Cancer Res. 2017 Jun 15;77(12):3268-3279. doi: 10.1158/0008-5472.CAN-16-3126. Epub 2017 Apr 11.

16.

CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.

Manic G, Signore M, Sistigu A, Russo G, Corradi F, Siteni S, Musella M, Vitale S, De Angelis ML, Pallocca M, Amoreo CA, Sperati F, Di Franco S, Barresi S, Policicchio E, De Luca G, De Nicola F, Mottolese M, Zeuner A, Fanciulli M, Stassi G, Maugeri-Saccà M, Baiocchi M, Tartaglia M, Vitale I, De Maria R.

Gut. 2018 May;67(5):903-917. doi: 10.1136/gutjnl-2016-312623. Epub 2017 Apr 7.

17.

Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinoma.

Po A, Silvano M, Miele E, Capalbo C, Eramo A, Salvati V, Todaro M, Besharat ZM, Catanzaro G, Cucchi D, Coni S, Di Marcotullio L, Canettieri G, Vacca A, Stassi G, De Smaele E, Tartaglia M, Screpanti I, De Maria R, Ferretti E.

Oncogene. 2017 Aug 10;36(32):4641-4652. doi: 10.1038/onc.2017.91. Epub 2017 Apr 3.

18.

Squamous Cell Tumors Recruit γδ T Cells Producing either IL17 or IFNγ Depending on the Tumor Stage.

Lo Presti E, Toia F, Oieni S, Buccheri S, Turdo A, Mangiapane LR, Campisi G, Caputo V, Todaro M, Stassi G, Cordova A, Moschella F, Rinaldi G, Meraviglia S, Dieli F.

Cancer Immunol Res. 2017 May;5(5):397-407. doi: 10.1158/2326-6066.CIR-16-0348. Epub 2017 Mar 28.

19.

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.

Milella M, Falcone I, Conciatori F, Matteoni S, Sacconi A, De Luca T, Bazzichetto C, Corbo V, Simbolo M, Sperduti I, Benfante A, Del Curatolo A, Cesta Incani U, Malusa F, Eramo A, Sette G, Scarpa A, Konopleva M, Andreeff M, McCubrey JA, Blandino G, Todaro M, Stassi G, De Maria R, Cognetti F, Del Bufalo D, Ciuffreda L.

Sci Rep. 2017 Feb 21;7:43013. doi: 10.1038/srep43013.

20.

Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers.

Bon G, Loria R, Amoreo CA, Verdina A, Sperduti I, Mastrofrancesco A, Soddu S, Diodoro MG, Mottolese M, Todaro M, Stassi G, Milella M, De Maria R, Falcioni R.

Oncotarget. 2016 Aug 19;8(65):108463-108479. doi: 10.18632/oncotarget.11400. eCollection 2017 Dec 12.

21.

ΔNp63 drives metastasis in breast cancer cells via PI3K/CD44v6 axis.

Di Franco S, Turdo A, Benfante A, Colorito ML, Gaggianesi M, Apuzzo T, Kandimalla R, Chinnici A, Barcaroli D, Mangiapane LR, Pistone G, Vieni S, Gulotta E, Dieli F, Medema JP, Stassi G, De Laurenzi V, Todaro M.

Oncotarget. 2016 Aug 23;7(34):54157-54173. doi: 10.18632/oncotarget.11022.

22.

A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype.

Fessler E, Jansen M, De Sousa E Melo F, Zhao L, Prasetyanti PR, Rodermond H, Kandimalla R, Linnekamp JF, Franitza M, van Hooff SR, de Jong JH, Oppeneer SC, van Noesel CJ, Dekker E, Stassi G, Wang X, Medema JP, Vermeulen L.

Oncogene. 2016 Nov 17;35(46):6026-6037. doi: 10.1038/onc.2016.134. Epub 2016 May 9.

23.

Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance.

De Angelis ML, Zeuner A, Policicchio E, Russo G, Bruselles A, Signore M, Vitale S, De Luca G, Pilozzi E, Boe A, Stassi G, Ricci-Vitiani L, Amoreo CA, Pagliuca A, Francescangeli F, Tartaglia M, De Maria R, Baiocchi M.

Stem Cells Transl Med. 2016 Apr;5(4):511-23. doi: 10.5966/sctm.2015-0214. Epub 2016 Mar 8.

24.

Epithelial-mesenchymal transition: a new target in anticancer drug discovery.

Marcucci F, Stassi G, De Maria R.

Nat Rev Drug Discov. 2016 May;15(5):311-25. doi: 10.1038/nrd.2015.13. Epub 2016 Jan 29.

PMID:
26822829
25.

Activated Thyroid Hormone Promotes Differentiation and Chemotherapeutic Sensitization of Colorectal Cancer Stem Cells by Regulating Wnt and BMP4 Signaling.

Catalano V, Dentice M, Ambrosio R, Luongo C, Carollo R, Benfante A, Todaro M, Stassi G, Salvatore D.

Cancer Res. 2016 Mar 1;76(5):1237-44. doi: 10.1158/0008-5472.CAN-15-1542. Epub 2015 Dec 16.

26.

Betulinic Acid Kills Colon Cancer Stem Cells.

Potze L, di Franco S, Kessler JH, Stassi G, Medema JP.

Curr Stem Cell Res Ther. 2016;11(5):427-33.

PMID:
26647913
27.

Apoptosis induced by a HIPK2 full-length-specific siRNA is due to off-target effects rather than prevalence of HIPK2-Δe8 isoform.

Di Rocco G, Verdina A, Gatti V, Virdia I, Toietta G, Todaro M, Stassi G, Soddu S.

Oncotarget. 2016 Jan 12;7(2):1675-86. doi: 10.18632/oncotarget.6423.

28.

γδ T cell-based anticancer immunotherapy: progress and possibilities.

Meraviglia S, Lo Presti E, Dieli F, Stassi G.

Immunotherapy. 2015;7(9):949-51. doi: 10.2217/imt.15.68. Epub 2015 Aug 27. Review. No abstract available.

PMID:
26569071
29.

Intragenic G-quadruplex structure formed in the human CD133 and its biological and translational relevance.

Zizza P, Cingolani C, Artuso S, Salvati E, Rizzo A, D'Angelo C, Porru M, Pagano B, Amato J, Randazzo A, Novellino E, Stoppacciaro A, Gilson E, Stassi G, Leonetti C, Biroccio A.

Nucleic Acids Res. 2016 Feb 29;44(4):1579-90. doi: 10.1093/nar/gkv1122. Epub 2015 Oct 27.

30.

Role of Paricalcitol in Modulating the Immune Response in Patients with Renal Disease.

Lucisano S, Arena A, Stassi G, Iannello D, Montalto G, Romeo A, Costantino G, Lupica R, Cernaro V, Santoro D, Buemi M.

Int J Endocrinol. 2015;2015:765364. doi: 10.1155/2015/765364. Epub 2015 Sep 15.

31.

Dynamic regulation of the cancer stem cell compartment by Cripto-1 in colorectal cancer.

Francescangeli F, Contavalli P, De Angelis ML, Baiocchi M, Gambara G, Pagliuca A, Fiorenzano A, Prezioso C, Boe A, Todaro M, Stassi G, Castro NP, Watanabe K, Salomon DS, De Maria R, Minchiotti G, Zeuner A.

Cell Death Differ. 2015 Oct;22(10):1700-13. doi: 10.1038/cdd.2015.19. Epub 2015 Mar 20.

32.

miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance.

De Cola A, Volpe S, Budani MC, Ferracin M, Lattanzio R, Turdo A, D'Agostino D, Capone E, Stassi G, Todaro M, Di Ilio C, Sala G, Piantelli M, Negrini M, Veronese A, De Laurenzi V.

Cell Death Dis. 2015 Jul 16;6:e1823. doi: 10.1038/cddis.2015.192.

33.

Almond Skin Inhibits HSV-2 Replication in Peripheral Blood Mononuclear Cells by Modulating the Cytokine Network.

Arena A, Bisignano C, Stassi G, Filocamo A, Mandalari G.

Molecules. 2015 May 15;20(5):8816-22. doi: 10.3390/molecules20058816.

34.

Normal vs cancer thyroid stem cells: the road to transformation.

Zane M, Scavo E, Catalano V, Bonanno M, Todaro M, De Maria R, Stassi G.

Oncogene. 2016 Feb 18;35(7):805-15. doi: 10.1038/onc.2015.138. Epub 2015 May 11. Review.

PMID:
25961919
35.

Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study.

D'Arcangelo M, Todaro M, Salvini J, Benfante A, Colorito ML, D'Incecco A, Landi L, Apuzzo T, Rossi E, Sani S, Stassi G, Cappuzzo F.

PLoS One. 2015 May 8;10(5):e0125037. doi: 10.1371/journal.pone.0125037. eCollection 2015.

36.

A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology.

Tate CM, Mc Entire J, Pallini R, Vakana E, Wyss L, Blosser W, Ricci-Vitiani L, D'Alessandris QG, Morgante L, Giannetti S, Larocca LM, Todaro M, Benfante A, Colorito ML, Stassi G, De Maria R, Rowlinson S, Stancato L.

PLoS One. 2015 Apr 28;10(4):e0125697. doi: 10.1371/journal.pone.0125697. eCollection 2015.

37.

By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy.

Petrelli A, Carollo R, Cargnelutti M, Iovino F, Callari M, Cimino D, Todaro M, Mangiapane LR, Giammona A, Cordova A, Montemurro F, Taverna D, Daidone MG, Stassi G, Giordano S.

Oncotarget. 2015 Feb 10;6(4):2315-30. Erratum in: Oncotarget. 2019 Aug 13;10(48):5003-5004.

38.

Colorectal cancer stem cells: from the crypt to the clinic.

Zeuner A, Todaro M, Stassi G, De Maria R.

Cell Stem Cell. 2014 Dec 4;15(6):692-705. doi: 10.1016/j.stem.2014.11.012. Review.

39.

γδ T cells as a potential tool in colon cancer immunotherapy.

Ramutton T, Buccheri S, Dieli F, Todaro M, Stassi G, Meraviglia S.

Immunotherapy. 2014;6(9):989-99. doi: 10.2217/imt.14.59. Review.

PMID:
25341120
40.

Lipid droplets: a new player in colorectal cancer stem cells unveiled by spectroscopic imaging.

Tirinato L, Liberale C, Di Franco S, Candeloro P, Benfante A, La Rocca R, Potze L, Marotta R, Ruffilli R, Rajamanickam VP, Malerba M, De Angelis F, Falqui A, Carbone E, Todaro M, Medema JP, Stassi G, Di Fabrizio E.

Stem Cells. 2015 Jan;33(1):35-44. doi: 10.1002/stem.1837.

41.

Estrogens and stem cells in thyroid cancer.

Zane M, Catalano V, Scavo E, Bonanno M, Pelizzo MR, Todaro M, Stassi G.

Front Endocrinol (Lausanne). 2014 Jul 25;5:124. doi: 10.3389/fendo.2014.00124. eCollection 2014. Review.

42.

Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer.

Zeuner A, Francescangeli F, Contavalli P, Zapparelli G, Apuzzo T, Eramo A, Baiocchi M, De Angelis ML, Biffoni M, Sette G, Todaro M, Stassi G, De Maria R.

Cell Death Differ. 2014 Dec;21(12):1877-88. doi: 10.1038/cdd.2014.105. Epub 2014 Jul 18.

43.

Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment.

Ciavardelli D, Rossi C, Barcaroli D, Volpe S, Consalvo A, Zucchelli M, De Cola A, Scavo E, Carollo R, D'Agostino D, Forlì F, D'Aguanno S, Todaro M, Stassi G, Di Ilio C, De Laurenzi V, Urbani A.

Cell Death Dis. 2014 Jul 17;5:e1336. doi: 10.1038/cddis.2014.285.

44.

CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis.

Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S, Cocorullo G, Gulotta G, Dieli F, De Maria R, Stassi G.

Cell Stem Cell. 2014 Mar 6;14(3):342-56. doi: 10.1016/j.stem.2014.01.009.

45.

p63 isoforms regulate metabolism of cancer stem cells.

D'Aguanno S, Barcaroli D, Rossi C, Zucchelli M, Ciavardelli D, Cortese C, De Cola A, Volpe S, D'Agostino D, Todaro M, Stassi G, Di Ilio C, Urbani A, De Laurenzi V.

J Proteome Res. 2014 Apr 4;13(4):2120-36. doi: 10.1021/pr4012574. Epub 2014 Mar 19.

PMID:
24597989
46.

TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells.

Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Benedetto AD, Todaro M, Stassi G, Sperati F, Amabile MI, Pilozzi E, Patrizii M, Biffoni M, Maugeri-Saccà M, Piccolo S, De Maria R.

Oncogene. 2015 Feb 5;34(6):681-90. doi: 10.1038/onc.2014.5. Epub 2014 Feb 17.

PMID:
24531710
47.

Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4.

Volonté A, Di Tomaso T, Spinelli M, Todaro M, Sanvito F, Albarello L, Bissolati M, Ghirardelli L, Orsenigo E, Ferrone S, Doglioni C, Stassi G, Dellabona P, Staudacher C, Parmiani G, Maccalli C.

J Immunol. 2014 Jan 1;192(1):523-32. doi: 10.4049/jimmunol.1301342. Epub 2013 Nov 25.

48.

Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells.

Todaro M, Meraviglia S, Caccamo N, Stassi G, Dieli F.

Oncoimmunology. 2013 Sep 1;2(9):e25821. Epub 2013 Jul 29.

49.

Tumor and its microenvironment: a synergistic interplay.

Catalano V, Turdo A, Di Franco S, Dieli F, Todaro M, Stassi G.

Semin Cancer Biol. 2013 Dec;23(6 Pt B):522-32. doi: 10.1016/j.semcancer.2013.08.007. Epub 2013 Sep 4. Review.

PMID:
24012661
50.

Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy.

Todaro M, Turdo A, Bartucci M, Iovino F, Dattilo R, Biffoni M, Stassi G, Federici G, De Maria R, Zeuner A.

Cancer Res. 2013 Nov 1;73(21):6393-400. doi: 10.1158/0008-5472.CAN-13-0248. Epub 2013 Sep 5.

Supplemental Content

Loading ...
Support Center